CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.
February 11th 2025
Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.
Elie Fahed, MD, provides an overview of what multiple myeloma is, and Beth walks us through her frustrating journey to initial diagnosis as an atypical patient.
FDA Grants Priority Review to Melflufen-Dexamethasone Combination for Multiple Myeloma
September 4th 2020The Food and Drug Administration granted a priority review to the new drug application for melflufen in combination with dexamethasone for adults with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy.
Ninlaro Found to Be Effective and Safe for Treatment of Newly Diagnosed Multiple Myeloma
August 28th 2020In addition to improving progression-free survival, researchers have found single-agent Ninlaro (ixazomib) to be a tolerable option in patients with newly diagnosed multiple myeloma who have also already undergone an autologous stem cell transplant.
Clinical Trials Are Pivotal in the Evolution of CAR-T Cell Therapy in Multiple Myeloma
August 18th 2020While the use of CAR-T cell therapy is currently still being investigated in patients with multiple myeloma, Dr. Nina Shah of the UCSF Helen Diller Family Comprehensive Cancer Center believes that these clinical trials will be what ultimately moves the field forward.
Early Mobility Program For Patients With Cancer Helps to Maintain or Improve Their Mobility
July 29th 2020The use of a mobility aide program in a cancer unit among the Mount Sinai Health System helped 76% of patients hospitalized for their cancer either maintain or improve their mobility scores, helping to reduce excess days spent in the hospital and readmission rates.
FDA Panel Unanimously Supports Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma
July 15th 2020The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted in favor of the agency approving belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma who have previously received at least four therapies.
Standard of Care in Newly Diagnosed Myeloma Remains as Carfilzomib Triplet Does Not Improve Outcomes
May 30th 2020New findings, presented at the 2020 ASCO Virtual Scientific Program, suggest that the standard of care for newly diagnosed patients with multiple myeloma remains as Kyprolis triplet does not improve outcomes.
COVID-19's Impact on How Patients with CLL, Myeloma Have Received Treatment
May 4th 2020In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients”, Dr. Farukh Awan addresses how the new coronavirus has impacted patient care for those diagnosed with chronic lymphocytic leukemia and myeloma.